Recently, researchers introduced a groundbreaking lentiviral platform designed to enable the in vivo delivery of stably integrating genetic medicines directly to T and NK cells, eliminating the need for traditional lymphodepleting chemotherapy. This platform utilizes a novel detargeted viral fusogen and a cell-specific targeting moiety to achieve precise delivery, offering a less invasive and more streamlined approach to cellular engineering. By bypassing the complexities of ex vivo cell manipulation and conditioning regimens, this technology holds the potential to make CAR-based therapies significantly more accessible, paving the way for off-the-shelf treatments that can reach a broader patient population.
SHARE
